Cytokine-Induced Killer Cells — Competitive Intelligence Brief

Cytokine-Induced Killer Cells (Cytokine-Induced Killer Cells) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cell therapy; autologous T cell therapy. Area: Oncology.

phase 3 Cell therapy; autologous T cell therapy Oncology Biologic

Target snapshot

Cytokine-Induced Killer Cells (Cytokine-Induced Killer Cells) — The First People's Hospital of Changzhou. Cytokine-Induced Killer (CIK) cells are ex vivo expanded autologous T lymphocytes that recognize and kill tumor cells through both MHC-restricted and non-restricted pathways.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Cytokine-Induced Killer Cells TARGET	Cytokine-Induced Killer Cells	The First People's Hospital of Changzhou	phase 3	Cell therapy; autologous T cell therapy
Casgevy	EXAGAMGLOGENE AUTOTEMCEL		marketed	Autologous genome-edited hematopoietic stem cell therapy	BCL11A	2023-01-01
Allogenix Plus	Allogenix Plus	University of Missouri-Columbia	marketed	Allogeneic cell therapy
MC	MC	Aivita Biomedical, Inc.	marketed	Mesenchymal stem cell therapy
Mesenchymal Stem Cells (MSCs)	Mesenchymal Stem Cells (MSCs)	The Cleveland Clinic	marketed	Cell therapy
ASC	ASC	Anterogen Co., Ltd.	marketed	Autologous stem cell therapy
IL-7/IL-15 pre-treated CD19 cells	IL-7/IL-15 pre-treated CD19 cells	jiangjingting	marketed	CAR-T cell therapy	CD19

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cell therapy; autologous T cell therapy class)

1. The First People's Hospital of Changzhou · 1 drug in this class